文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

肥胖与血浆脂肪细胞因子在脓毒症患者免疫失调中的作用

THE ROLE OF OBESITY AND PLASMA ADIPOCYTOKINES IN IMMUNE DYSREGULATION IN SEPSIS PATIENTS.
PubMed 文献 · Shock · 2022-12-02
一句话结论在脓毒症患者中,肥胖及BMI相关脂肪细胞因子与铁蛋白和mHLA-DR定义的免疫失调无关;抵抗素与免疫反应和28天死亡率相关,且在各BMI组相似。

该研究为前瞻性研究的二次分析,纳入167例因肺炎、菌血症或急性胆管炎诊断脓毒症的患者,检测瘦素、脂联素和抵抗素血浆浓度,比较正常体重(BMI 18.5-24.9 kg/m²,n=67)、超重(BMI 25.0-29.9 kg/m²,n=56)和肥胖(BMI≥30 kg/m²,n=42)患者及免疫内型(高炎症n=40、免疫麻痹n=62、未分类n=55)间的差异。结果显示肥胖患者瘦素浓度高于正常体重(P=0.008)和超重(P=0.02)患者,而脂联素和抵抗素无差异(P=0.08和P=0.85)。抵抗素与免疫内型相关,高炎症患者最高(P<0.001),且可预测28天死亡率(校正OR 1.03每10 ng/mL,P=0.04)。结论认为肥胖和BMI相关脂肪细胞因子与脓毒症免疫失调无关,抵抗素与临床结局的关系可能由炎症反应驱动而非肥胖本身。

要点

  • 肥胖脓毒症患者瘦素浓度高于正常体重(P=0.008)和超重(P=0.02)患者,但脂联素和抵抗素无差异(P=0.08和P=0.85)。
  • 抵抗素浓度与免疫内型相关,高炎症患者最高(P<0.001),且预测28天死亡率(校正OR 1.03每10 ng/mL,P=0.04)。
  • 瘦素和脂联素未显示与免疫内型或28天死亡率的关联。
  • 肥胖及BMI相关脂肪细胞因子与铁蛋白和mHLA-DR定义的免疫失调无关。
  • 抵抗素与临床结局的关联在正常体重、超重和肥胖患者中相似,提示由炎症反应驱动而非肥胖本身。

适用人群与场景

  • 因肺炎、菌血症或急性胆管炎诊断脓毒症的患者,共167例,按BMI分为正常体重(18.5-24.9 kg/m²,n=67)、超重(25.0-29.9 kg/m²,n=56)和肥胖(≥30 kg/m²,n=42)。

诊断标准与关键阈值

  • 免疫内型定义:高炎症(n=40)、免疫麻痹(n=62)、未分类(n=55),依据铁蛋白和mHLA-DR表达定义。

研究设计与关键结果

  • 研究类型:前瞻性研究的二次分析;样本量167例;人群为因肺炎、菌血症或急性胆管炎诊断脓毒症的患者。
  • 肥胖患者瘦素浓度高于正常体重(P=0.008)和超重(P=0.02)患者;脂联素和抵抗素浓度在BMI组间无差异(P=0.08和P=0.85)。
  • 抵抗素浓度与免疫内型相关,高炎症患者最高(P<0.001)。
  • 抵抗素浓度预测28天死亡率(校正OR 1.03每10 ng/mL,P=0.04);瘦素和脂联素未显示此关联。
  • 肥胖及BMI相关脂肪细胞因子与铁蛋白和mHLA-DR定义的免疫失调无关;抵抗素与免疫反应和不良临床结局的关联在正常体重、超重和肥胖患者中相似。

证据类型、等级与局限

  • 证据类型:前瞻性研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,肥胖和BMI相关脂肪细胞因子在脓毒症患者免疫失调中不起作用。
  • 作者认为,抵抗素与临床结局的关系可能由炎症反应驱动而非肥胖本身。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Introduction: The dysregulated immune response in sepsis is highly variable, ranging from hyperinflammation to immunoparalysis. Obesity is associated with the release of inflammatory mediators from adipose tissue, known as adipocytokines, causing a chronic inflammatory state. Perhaps counterintuitively, obesity is also associated with lower mortality in sepsis patients. We investigated the association between obesity, circulating adipocytokine concentrations, immune dysregulation, and outcome in sepsis patients. Methods In this secondary analysis of a prospective study, plasma concentrations of the adipocytokines leptin, adiponectin, and resistin were assessed in 167 patients at diagnosis of sepsis due to pneumonia, bacteremia, or acute cholangitis. Adipocytokines were compared between patients with normal weight (body mass index [BMI], 18.5-24.9 kg/m 2 ; n = 67), overweight (BMI, 25.0-29.9 kg/m 2 ; n = 56), and obesity (BMI ≥30 kg/m 2 ; n = 42), as well as between immunological endotypes: hyperinflammation (n = 40), immunoparalysis (n = 62), and unclassified (n = 55). Results: Higher circulating concentrations of leptin were observed in patients with obesity compared with patients with normal weight ( P = 0.008) and overweight ( P = 0.02), whereas adiponectin and resistin plasma concentrations were not different ( P = 0.08 and P = 0.85, respectively). Resistin concentrations were associated with immunological endotypes, with the highest levels found in hyperinflammatory patients ( P < 0.001). Furthermore, resistin concentrations were predictive for 28-day mortality (adjusted odds ratio, 1.03 per 10 ng/mL; P = 0.04). These associations were not found for leptin and adiponectin. Conclusion: Obesity and BMI-related adipocytokines are not related to the development of a hyperactive or suppressed immune response as defined by ferritin and mHLA-DR expression in sepsis patients. Although resistin is related to the immune response and an increased risk of adverse clinical outcomes, these associations are similar in patients with normal weight, overweight, and obesity. This implies that the relationship between resistin and clinical outcome is likely driven by the inflammatory response and not by obesity itself. Taken together, although there exists a strong association between inflammation and sepsis mortality, our results do not point toward a role for obesity and BMI-related adipocytokines in immune dysregulation in sepsis patients.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. de Nooijer AH, Antonakos N, Markopoulou D, et al. THE ROLE OF OBESITY AND PLASMA ADIPOCYTOKINES IN IMMUNE DYSREGULATION IN SEPSIS PATIENTS. Shock. 2022. PMID: 36455260. doi:10.1097/SHK.0000000000002063

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。